Erste Asset Management Gmb H Adaptimmune Therapeutics PLC Transaction History

Erste Asset Management Gmb H

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Nov 26, 2024	SELL	$1.05 - $2.53 $94,500 - $227,699	-90,000 Closed	0 $0
Q2 2022 Nov 26, 2024	BUY	$1.33 - $2.28 $119,700 - $205,199	90,000 New	90,000 $154 Million
Q4 2021 Nov 22, 2024	BUY	$3.5 - $5.68 $315,000 - $511,200	90,000 New	90,000 $333 Million
Q3 2021 Nov 22, 2024	BUY	$3.44 - $6.37 $309,600 - $573,300	90,000 New	90,000 $468 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $114M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.